Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in Metastatic Renal Cell Carcinoma
NCT00126659Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jan 2006
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sorafenib in clear cell renal cell carcinoma (ccRCC) (3 arms), sponsored by National Cancer Institute. Primary endpoints: Response Rate, Toxicities of BAY 43-9006 and 1 more. Started Jan 2006; status: terminated.
02
Drugs
sorafenib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT00126659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00126659.